CLRB Stock Summary and Trading Ideas (Cellectar Biosciences | NASDAQ:CLRB)

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.

Cellectar Biosciences trades on the NASDAQ stock market under the symbol CLRB.

As of April 15, 2024, CLRB stock price declined to $3.32 with 838,768 million shares trading.

CLRB has a beta of 1.65, meaning it tends to be more sensitive to market movements. CLRB has a correlation of 0.07 to the broad based SPY ETF.

CLRB has a market cap of $33.01 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, CLRB stock traded as high as $18.40 and as low as $1.25.

The top ETF exchange traded funds that CLRB belongs to (by Net Assets): VTI, VXF.

CLRB has outperformed the market in the last year with a return of +137.1%, while the SPY ETF gained +23.9%. However, in the most recent history, CLRB shares have underperformed the stock market with its stock returning -5.4% in the last 3 month period and -15.3% for the last 2 week period, while SPY has returned +6.2% and -3.4%, respectively.

CLRB support price is $3.35 and resistance is $3.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLRB stock will trade within this expected range on the day.